FDA has approved Merck’s adjuvant combination of Welireg (belzutifan) plus Keytruda (pembrolizumab) for patients with clear cell renal cell carcinoma after surgery, setting a new standard for high-risk disease in the post-operative setting. The regimen pairs a HIF-2α inhibitor with an immune checkpoint antibody. The approval follows Dana-Farber research backing the pairing, reflecting a continued push to convert targeted oncology biology into clinically meaningful, durable outcomes in earlier-stage RCC. For Merck, the decision extends Keytruda’s footprint into additional adjuvant and targeted combinations. Clinically, the move puts pressure on alternative adjuvant strategies that do not incorporate HIF-2α pathway modulation, particularly as patient selection for post-surgical intensification becomes more central to regulatory and reimbursement discussions.